CHMP gives positive opinion for Novo’s Sogroya in idiopathic short stature
CHMP issued a positive opinion for Novo Nordisk’s Sogroya (somapacitan) for children with idiopathic short stature in Europe. If approved, it would be the first and only growth hormone treatment approved for this indication in the EU.
Novo Nordisk said Sogroya® (somapacitan) would be the first and only growth hormone treatment approved for idiopathic short stature in the EU if it is approved, offering a treatment option for children and their families affected by the condition. Bagsværd, Denmark, 18 September 2026 — Novo Nordisk today wel…